BI-1206 + rituximab + acalabrutinib

This is a combination therapy comprising **BI-1206**, **rituximab**, and **acalabrutinib**. - **BI-1206** is a monoclonal antibody that targets CD32b (FcγRIIB), an immune checkpoint receptor expressed on B cells which can contribute to resistance to anti-CD20 therapies. By antagonizing CD32b, BI-1206 aims to enhance the efficacy of anti-CD20 antibodies like rituximab[1][5]. - **Rituximab** is a monoclonal antibody that targets CD20 on B cells, leading to cell death predominantly via antibody-dependent cellular cytotoxicity (ADCC), phagocytosis (ADCP), and complement-dependent cytotoxicity (CDC)[2][5]. - **Acalabrutinib** is a second-generation Bruton's tyrosine kinase (BTK) inhibitor, blocking B-cell receptor signaling needed for malignant B-cell survival[2][6]. This triple combination is being explored for **relapsed or refractory B-cell lymphomas and chronic lymphocytic leukemia**, aiming to overcome resistance to anti-CD20 therapy and deepen remission, leveraging complementary mechanisms: BI-1206 overcomes rituximab resistance, rituximab depletes B cells, and acalabrutinib interrupts BTK signaling[1][2][5].

Other names

BI-1206 + rituximab + acalabrutinib